The USPSTF concludes with moderate certainty that women with increased calculated risk can benefit from SERM
therapy to reduce the incidence of invasive hormone receptor-positive breast cancer.
and AI use was measured between May 2006 and December 2007.
Currently available treatment options will allow for the clinician to better individualize therapy and address a variety of patient needs and concerns, while the quest for the perfect SERM
The newer agents seem to have more potent estrogenic effects on bone than are seen with raloxifene and, at the same time, may not be associated with increased endometrial thickness or other uterine effects, a concern that developed with other SERMs
that were being investigated for postmenopausal osteoporosis.
they do not block estrogens at the receptor site as SERMs
Taylor, professor in the Department of Obstetrics, Gynecology and Reproductive Sciences at Yale, and his colleagues treated breast and endometrial cell lines with either estrogen or estrogen plus one of the SERMs
5) Thus I believe ospemifene's effect on the endometrium is much more akin to the SERM
raloxifene than it is to estrogen.
The randomized trials were primarily performed by oncologists, but the application of SERM
prevention falls largely on the primary care community, which cares for patients at risk for breast cancer.
Komm and colleagues describe substudies of the Selective estrogens, Menopause, and Response to Therapy (SMART) trials to evaluate the combination of conjugated estrogens and SERMs
to prevent osteoporosis in postmenopausal women with a uterus.
Pfizer submitted a new drug application to the Food and Drug Administration in 2007, and in 2008 an advisory panel voted 9-3 that the benefits of the SERM
outweighed this risk in postmenopausal women with osteoporosis.
This is disappointing because as an antiosteoporosis drug we really need to have a SERM
that would not only reduce vertebral fractures, but nonvertebral fractures as well," explained Dr.